Perspectives
Nature Reviews Drug Discovery 4, 961-967 (December 2005) | doi:10.1038/nrd1904
Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology
Jan van der Greef1 & Robert N. McBurney2 About the authors
Top of page
Abstract
The pharmaceutical industry is currently beleaguered by close scrutiny from the financial community, regulators and the general public. Productivity, in terms of new drug approvals, has generally been falling for almost a decade and the safety of a number of highly successful drugs has recently been brought into question. Here, we discuss whether taking an in vivo systems approach to drug discovery and development could be the paradigm shift that rescues the industry.
Author affiliations
-
Jan van der Greef is at TNO Systems Biology, Netherlands Organization for Applied Scientific Research, Utrechtseweg 48, PO BOX 360, 3700 AJ Zeist, The Netherlands; Centre for Medical Systems Biology/Leiden Amsterdam Centre for Drug Research, Einsteinweg 55, PO BOX 9502, 2300 RA Leiden, The Netherlands; and BG Medicine, Inc., 610 North Lincoln Street, Waltham, Massachusetts 02451, USA.
Email: vanderGreef@voeding.tno.nl -
Robert N. McBurney is at BG Medicine, Inc., 610N Lincoln Street, Waltham, Massachusetts 02451, USA.
Email: RMcBurney@bg-medicine.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Selectivity of Pyripyropene Derivatives in Inhibition toward Acyl-CoA:cholesterol Acyltransferase 2 IsozymeThe Journal of Antibiotics Original Article
